These findings confirmed that upregulated TET1 and TRPV4 expression in the L4–6 DRG sustained the allodynia in CIBP while a targeted intervention after the inhibition of TET1 or TRPV4 activity may represent a novel therapeutic approach to ameliorating bone-cancer-related pain [125]. This evidence concerns the gene TET1 and bone neoplasm.